Novo Nordisk has introduced a new pricing strategy for its weight-loss drugs, Ozempic and Wegovy. Starting now, people without insurance can buy the lowest doses for $199 a month for two months. After that, the price jumps to $349. This deal is available through the drugs' websites and select pharmacies. The lower price only applies to the 0. 25 mg and 0. 5 mg doses...
Eli Lilly is making waves in the weight loss drug market with its new obesity pill, orforglipron. This pill is set to compete with Novo Nordisk's oral semaglutide, which has shown promising results. Both drugs work by mimicking a gut hormone called GLP-1 to help control appetite and blood sugar levels. Eli Lilly's pill is a small-molecule drug, which means it is abs...
A major shakeup is happening at Novo Nordisk. The company's CEO, Lars Fruergaard Jørgensen, is stepping down. This move comes as the company faces tough times in the market. Novo Nordisk is known for its weight-loss drugs, like Wegovy. But lately, things haven't been easy for them. The pharmaceutical company is dealing with a lot of competition. Other companies are ...
The battle over semaglutide, the active ingredient in popular diabetes and weight loss drugs, has reached a critical point. A federal judge in Texas recently ruled against compounding pharmacies, siding with a major drug manufacturer. This decision means that these pharmacies can no longer produce cheaper, unapproved versions of Wegovy and Ozempic. This ruling comes ...
Novo Nordisk, a big player in Europe's pharma scene, saw its shares take a huge hit on Friday. Why? Their latest weight-loss drug, CagriSema, didn't meet expectations. The drug helped patients lose about 22. 7% of their body weight in late-stage trials, but that was barely better than Eli Lilly's rival drug, Mounjaro. Only around half of the patients got the highest ...
This morning, there's a lot to unpack! Did you know that McDonald's distanced itself from Trump's drive-through stunt? They're claiming no involvement in his surprise fast-food appearance. On a health note, Novo Nordisk's Ozempic pill might reduce heart attack and stroke risks, according to a fresh study. Trump's Social Security plans aren't scoring well with budget-...
Lawmakers have been questioning Novo Nordisk, the company behind popular weight loss drugs Ozempic and Wegovy. The Senate wants to know why these medications are priced so much higher in the U.S. compared to other countries. For example, Americans with diabetes pay $969 per month for Ozempic, while Canadians pay just $155. The CEO of Novo Nordisk, Lars Fruergaard Jør...
Imagine a world where drugs cost differently based on where you live. That's what happened at a recent Senate hearing in Washington, D.C. Novo Nordisk's CEO, Lars Fruergaard Jorgensen, was asked some tough questions about the high prices of two important medications: Ozempic for diabetes and Wegovy for weight loss. Jorgensen blamed pharmacy benefit managers (PBMs) f...
Imagine a world where millions of Americans could potentially shed pounds and manage their diabetes with a single injection. At least 57 million privately insured adults under the age of 65 could be eligible for GLP-1s, a class of weight loss and diabetes medications. GLP-1s are approved to treat adults with Type 2 diabetes or obesity, or who are overweight with at...